1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Beijing Hotgen Biotech Co., Ltd.

Beijing Hotgen Biotech Co., Ltd.

688068.SS
Beijing Hotgen Biotech Co., Ltd.CN flagShanghai Stock Exchange
135.00
CNY
+12.03
- -
12.52BMarket Cap
Beijing Hotgen Biotech Co., Ltd.
688068.SS
(Shanghai Stock Exchange)

Recent

price

135.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.86
2.04
2.71
2.81
5.57
58.34
38.89
6.25
5.85
4.69
5.36
Revenue per Share
0.44
0.43
0.7
0.45
1.22
23.75
10.33
0.33
-2.36
-2.5
-2.82
Basic EPS, GAAP
0.37
-0.66
0.19
-0.92
-0.08
24.4
4.52
-5.27
-1.64
-1.47
-0.27
Free Cash Flow per Basic Share
0.04
- -
- -
0.01
0.21
1.01
3.4
- -
0.21
0.02
0.07
Dividend per Share
1.06
1.39
2.02
2.48
2.91
25.58
32.85
34.67
32.17
29.96
31.58
Book Value per Share
1.99
2.18
2.89
8.53
7.47
30.6
36.05
37.78
34.38
30.17
33.16
Tangible Book Value per Share
66
70
69
75
92
92
91
88
87
86
87
Basic Weighted Avg Shares
122
142
187
210
514
5,369
3,557
548
510
405
466
Sales/Revenue/Turnover
26.22
23.95
29.53
17.73
23.3
49.76
34.84
-0.07
-35.21
-61.62
-32.07
Operating Margin (%)
8
10
17
22
29
68
120
71
93
82
- -
Depreciation Expense
29
30
48
34
112
2,186
945
29
-206
-216
-245
Net Income, GAAP
15.13
13.06
13.17
10.86
12.66
14.7
13.96
- -
- -
- -
42.9
Effective Tax Rate (%)
23.57
21.16
25.73
16.1
21.82
40.71
26.56
5.28
-40.36
-53.36
-52.56
Profit Margin (%)
93
68
74
504
437
1,784
1,287
652
1,023
1,349
1,040
Working Capital
- -
- -
- -
21
17
23
14
8
- -
- -
- -
LT Debt
131
162
210
649
747
2,874
3,354
3,366
3,050
2,657
2,934
Total Equity
- -
19.44
25.34
7.5
14.32
119.18
33.14
- -
- -
- -
- -
Return on Invested Capital (%)
- -
35.55
40.57
19.73
44.37
159.73
35.23
- -
- -
- -
-1.99
Return on Capital (%)
- -
36.24
40.74
20.81
49.41
166.71
35.26
0.96
-7.04
-8.01
-8.56
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
43
50
50
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
93
Market Capitalization
5,210
8,308
12,189

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,308
1,470
1,337
Cash, Cash Equivalents & STI
484
738
583
Accounts Receivable, Net
91
114
102
Inventories
86
80
80
Total Current Liabilities
285
273
297
Payables & Accruals
- -
- -
- -
ST Debt
43
50
50
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
55.92%
-12.9%
Free Cash Flow
- -
-5,968.89%
-11.22%
Net Income, GAAP
- -
178.05%
4.99%
Sales/Revenue/Turnover
- -
159.93%
-20.58%
Total Cash Common Dividend
- -
- -
-90.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
116
133
137
125
510
2025
93
111
95
- -
405
2026
116
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
-2.36
2025
-0.43
- -
- -
- -
-2.5
2026
-0.77
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Similar Companies
Kuros Biosciences AG (CSBTF)
Eliem Therapeutics, Inc. (ELYM)
CureVac N.V. (CVAC)
Point of Care Nano-Technology, Inc. (PCNT)
Liquidia Corporation (LQDA)
Context Therapeutics Inc. (CNTX)
Business
Beijing Hotgen Biotech Co., Ltd. (688068.SS) is a China-based high-tech enterprise principally engaged in the research, development, manufacture and sale of in vitro diagnostic (IVD) reagents, instruments and related products for medical and public safety inspection in the biomedicine field; it operates eight major technology platforms including bioactive raw material development, sugar capture for abnormal protein detection, magnetic particle chemiluminescence, up-converting phosphor (UPT), colloidal gold immunochromatography, enzyme-linked immunoassay, molecular diagnostics and instrument R&D. The company offers a comprehensive portfolio of diagnostic solutions such as the award-winning UPT platform for point-of-care testing (POCT), high-precision chemiluminescence immunoassay (CLIA) platforms including single-cartridge MQ60 series and full-automatic C2000 systems, colloidal gold (CG) rapid tests, enzyme-linked immunosorbent assay (ELISA) products, polymerase chain reaction (PCR) tests and IVD raw materials; specific test parameters cover over 100 markers for cardiovascular diseases, liver diseases, tumor markers like CA125, AFP, CEA, PSA, infectious diseases including respiratory pathogens, gastrointestinal infections, Ebola virus antigen, biological warfare agents and mycotoxins, as well as drug detection, CDC and food safety monitoring applications. Founded in 2005 and headquartered in Beijing's Daxing District Biomedical Base, Hotgen Biotech serves hospitals, township health centers, third-party testing institutions, disease control centers, public security, military, ports and food enterprises primarily in China with a nationwide marketing network, while its products are used by over 10,000 medical institutions worldwide and hold certifications including CE IVDR, FDA and NMPA; subsidiaries include Hotgen (Langfang), Hotgen (Jilin), Weikekang Technology and Shunjing Biological. In recent developments, the company announced positive preliminary results from the Phase Ib clinical study of SGC001, an innovative drug candidate from its affiliate Beijing Shunjing Biomedical Technology Co., Ltd., in 2025; it obtained 23 overseas qualification certifications for its products; and it reported a net loss of CNY 191.0 million for fiscal year 2024 amid ongoing expansion in innovative biological drugs and AI-driven services.